Westlake Aging Cohort (WeAC)
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age55-90
SponsorWestlake University
About this trial
The Westlake Ageing Cohort (WeAC) is a longitudinal cohort study conducted in Hangzhou, Zhejiang Province, China. The investigators aim to enroll 2,800 participants aged 55 years and older for long-term follow-up. The population will include individuals with neurodegenerative diseases or those at the prodromal stage of cognitive impairment, as well as healthy middle-aged and older adults serving as controls. The investigators will collect their sociodemographic, dietary, lifestyle, clinical, and neuroimaging data, as well as biological samples.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Age between 55 and 90 years (inclusive) at baseline.
Availability of a companion capable of providing independent functional assessments and fluent in Chinese.
Willingness and ability to regularly complete required surveys and physical examinations as per study protocol.
MMSE scores were required to be 24-30 (inclusive) for healthy controls and MCI; and 20-24 (inclusive) for AD and DLB/PDD patients.
Disqualifiers
Participants with major medical or neuropsychiatric conditions unrelated to the study purposes were excluded. These included, but were not limited to, psychiatric disorders, cancer, infectious diseases, structural brain abnormalities, and epilepsy.
Current use of psychoactive medications or any other drugs that may affect the study.
Participants with cardiac pacemakers, artificial heart valves, or metallic implants in the eyes, skin, or any other part of the body.
Participants with any other diseases that may affect the study.
Trial population
All participants must be Chinese residents, regardless of their ethnicity.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
Cognitive function
Cognitive function will be evaluated using the Mini-Mental State Examination (MMSE, score range: 0-30, with higher scores indicating better cognitive function) and clinical diagnosis provided by physicians.
Time frame
48 months2
Gut microbiome
The gut microbiome will be profiled by metagenomic sequencing or ITS rRNA sequencing. In addition, fecal microbiota will be cultured, isolated, and identified.
Time frame
48 monthsSecondary outcomes
1
Brain magnetic resonance imaging
Use brain magnetic resonance imaging (MRI) to measure the brain structure and function of participants.
Time frame
48 months2
Positron emission tomography
Assess the brain function and neurological disorders by positron emission tomography (PET).
Time frame
48 months3
Brain images relevant inspections
Other brain image relevant inspections required for study to measure brain structure and function of participants.
Time frame
48 months4
Electroencephalogram
Electroencephalogram (EEG) monitors the electrical activity of the brain. And further measure based on coupled EEG/MEG and eye-tracking.
Time frame
48 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Westlake University
Lead sponsor
Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University
Collaborator
The Third People's Hospital of Hangzhou
Collaborator
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: